Novartis’ new CEO Vasant Narasimhan has indicated that the company might spin off its struggling U.S. generic pill business—and that is what it is preparing to do, sources are telling Reuters.
The news service today reported that Novartis is doing the legwork to auction off that piece of the Sandoz business, which might bring $1.6 billion from a competitor or private investors, Reuters said.
Outgoing CEO Joseph Jimenez and Narasimhan told analysts late last year that the Swiss drugmaker was looking at its options for the business in the face of rapid price erosion for generic pills in the U.S. They said a spinoff was one idea.
Narasimhan, in his first earnings call last month, said the company was looking at how to optimize the business in the face of ”significant pricing declines” and a poor climate that was unlikely to change anytime soon.
Executives have said they will concentrate U.S. efforts in complex generics and biosimilars.
By Eric Palmer
Source: Fierce Pharma
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.